Autoimmune Gastrointestinal Dysmotility (AGID) Evaluation

Clinical Utility of AGID Evaluation

April 2012

This then can help distinguish autoimmune gastrointestinal dysmotility from chemotherapy side effects. Finally, a rising antibody titer in a previously seropositive patient can suggest cancer recurrence.

< Previous Slide

Clinical Utility of AGID Evaluation

Next Slide >

 

Jump to section:

• Introduction
• New Profile
• AGID
• Symptoms
• AGID¹
• AGID^1,2
• AGID: Laboratory Findings
• AGID: Antibody Evaluation
• Ganglionic Acetylcholine Receptor (AChR) Autoantibody^3,4
• Ganglionic AChR Autoantibody
• AGID Antibody Profile
• AGIDE/89886 Algorithm
• AGIDE/89886 Algorithm
• AGIDE/89886 Algorithm
• AGIDE/89886 Algorithm
• Clinical Utility of AGID Evaluation
• Clinical Utility of AGID Evaluation
• Summary
• References
• Questions